American Society of Hematology

ASH, the world's largest professional society concerned with the causes and treatments of blood disorders, regularly issues press releases highlighting clinical and research advances announced at the ASH annual meeting and published in Blood, as well as releases and statements on breaking policy news affecting the field of hematology.

Need to speak with an expert? Complete our Request An Expert form.

To be added to ASH's press release distribution list, contact Amanda Szabo at aszabo@hematology.org.

Latest Press Releases

  • New Data Shed Light on Potential Advantages of Pacritinib for Patients with Myelofibrosis Dec 06, 2016

    Compared with standard therapy, pacritinib significantly reduces spleen size among people with myelofibrosis who have very low levels of platelets, according to late-breaking study being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. The study investigators also reported that patients taking a twice-daily dose of this investigational oral multikinase inhibitor experienced significant improvements in symptoms.

  • Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit Dec 06, 2016

    Trial results being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone. The study is the largest randomized controlled trial of post-transplant therapy for multiple myeloma ever conducted in the United States.

  • First Multicenter Trial Finds CAR T-Cell Immunotherapy Effective, Feasible for Hard-to-Treat Lymphoma Dec 06, 2016

    A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising option for treating refractory non-Hodgkin lymphoma and practical to implement in a variety of real-world clinical settings. The study, which involved 22 institutions and tested a product called KTE-C19 (anti-CD19 CAR), is the first multicenter trial of this cellular immunotherapy-based treatment approach for lymphoma.

View all